The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients

Leukemia

Volumn 28, Issue 9, 2014, Pages 1804-1810

  Guglielmelli, P ^a   Lasho, T L ^b   Rotunno, G ^a   Score, J ^c   Mannarelli, C ^a   Pancrazzi, A ^a   Biamonte, F ^a   Pardanani, A ^b   Zoi, K ^d   Reiter, A ^e   Duncombe, A ^f   Fanelli, T ^a   Pietra, D ^g   Rumi, E ^b   Finke, C ^b   Gangat, N ^b   Ketterling, R P ^b   Knudson, R A ^b   Hanson, C A ^b   Bosi, A ^a   Pereira, A ^h   Manfredini, R ⁱ   Cervantes, F ^j   Barosi, G ^k   Cazzola, M ^g   Cross, N C P ^l   Vannucchi, A M ^a   Tefferi, A ^b   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b MAYO CLINIC   (United States)

^c WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF PAVIA   (Italy)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j UNIVERSITY OF BARCELONA   (Spain)

^k FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^l UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; CALRETICULIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN; SRSF2 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; PRIORITY JOURNAL; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALRETICULIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; REPRESSOR PROTEINS;

EID: 84908275738     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.76     Document Type: Article

References (21)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009; 59: 171-191
2. Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT., et al. Improving survival trends in primary myelofibrosis: an International Study. J Clin Oncol. 2012; 30: 2981-2987
3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for myelofibrosis research and treatment. Blood. 2009; 113: 2895-2901
4. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010; 115: 1703-1708
5. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S., et al. DIPSS Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011; 29: 392-397
6. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A., et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013; 27: 1861-1869
7. Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I., et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II Study. Blood. 2014; e-pub ahead of print 23 January. 2014; doi:10.1182/blood-2013-11-536557
8. Guglielmelli P, Nangalia J, Green AR, Vannucchi AM. CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. Am J Hematol. 2014; e-pub ahead of print 24 January. 2014; doi:10.1002/ajh.23678
9. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369: 2391-2405
10. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379-2390
11. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L., et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2013; e-pub ahead of print 26 December. 2013; doi:10.1182/blood-2013-11-538983
12. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD., et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2013; e-pub ahead of print 23 December. 2013; doi:10.1182/blood-2013-11-539098
13. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH., et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014; 28: 1472-1477
14. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C., et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014; 28: 1494-1500
15. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-951
16. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011; 29: 392-397
17. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL., et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011; 25: 82-88
18. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M., et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010; 116: 2857-2858
19. Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL., et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia. 2012; 26: 1439-1441
20. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I., et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014; e-pub ahead of print 29 January. 2014; doi:10.1182/ blood-2013-11-537167
21. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122: 3616-3627